乌拉地尔、硝苯地平、硫酸镁三联用药治疗妊娠期高血压对母婴结局的影响  

Effect of triple combination of urapidil, nifedipine and magnesium sulfate in the treatment of hypertension during pregnancy on maternal and infant outcomes

作　　者：李瑞荣 管晓燕 LI Ruirong;GUAN Xiaoyan(Department of Obstetrics and Gynecology,Nanle people’s Hospital,Puyang Henan 457400,China)

机构地区：[1]南乐县人民医院妇产科,河南濮阳457400

出　　处：《临床研究》2021年第12期55-58,共4页Clinical Research

摘　　要：目的探讨乌拉地尔、硝苯地平、硫酸镁三联用药治疗妊娠期高血压对母婴结局的影响。方法选取2019年1月至2020年12月南乐县人民医院妊娠期高血压患者101例,按照随机数字表法分为对照组(n=50例)和研究组(n=51例)。其中对照组给予硫酸镁治疗,研究组在对照组的基础上给予乌拉地尔、硝苯地平治疗。对比分析两组的疗效、血流指标、舒张压和收缩压水平、血清脂联素(APN)水平及高迁移率族蛋白1(HMGB1)水平、不良母婴结局。结果研究组的总有效率90.20%高于对照组的72.00%(P <0.05);两组治疗前血黏度和血细胞压积比较,差异均无统计学意义(P> 0.05),治疗后两组血黏度和血细胞压积均低于治疗前,且研究组均低于对照组(P <0.05);两组治疗前收缩压和舒张压比较,差异均无统计学意义(P> 0.05);两组治疗后收缩压和舒张压均低于治疗前,且研究组均低于对照组(P <0.05);两组治疗前血清APN和HMGB1比较,差异均无统计学意义(P> 0.05);两组治疗后血清APN均高于治疗前,且研究组高于对照组(P <0.05);两组治疗后血清HMGB1均低于治疗前,且研究组低于对照组(P <0.05);研究组的不良母婴结局总发生率7.84%低于对照组的32.00%(P <0.05)。结论乌拉地尔、硝苯地平、硫酸镁三联用药治疗妊娠期高血压疗效显著,可以有效改善母婴结局和血流指标水平。Objective To explore the effect of triple combination of urapidil, nifedipine and magnesium sulfate in the treatment of hypertension during pregnancy on maternal and infant outcomes. Methods A selection of 101 patients with hypertension during pregnancy in our hospital from January 2019 to December 2020 were divided into a control group(n=50 cases) and a study group(n=51 cases) according to the random number table. The control group was given magnesium sulfate treatment, and the study group was given urapidil and nifedipine on the basis of the control group. The efficacy, blood flow indicators, diastolic and systolic blood pressure levels, serum adiponectin(APN) levels, high mobility group protein 1(HMGB1) levels, and adverse maternal and infant outcomes were compared and analyzed between the two groups. Results The total effective rate of 90.20% in the study group was higher than 72.00% in the control group(P < 0.05);there was no significant difference in blood viscosity and hematocrit between the two groups before treatment(P > 0.05). Viscosity and hematocrit were lower than before treatment, and the study group was lower than the control group(P < 0.05);there was no significant difference in systolic and diastolic blood pressure between the two groups before treatment(P > 0.05);After treatment, the systolic and diastolic blood pressure were lower than before treatment, and the study group was lower than the control group(P < 0.05);there was no significant difference in serum APN and HMGB1 between the two groups before treatment(P > 0.05);two Serum APN after treatment in the group was higher than before treatment, and the study group was higher than the control group(P < 0.05);the serum HMGB1 after treatment in both groups was lower than before treatment,and the study group was lower than the control group(P < 0.05);The total incidence of adverse maternal and infant outcomes in the group was 7.84% lower than that of the control group 32.00%(P < 0.05). Conclusion The triple combination of Urapidil, Nifedipine, a

关 键 词：乌拉地尔 硝苯地平 硫酸镁 妊娠期高血压 母婴结局 

分 类 号：R714[医药卫生—妇产科学]